Injection & Infusion Therapy Fraud Defense
Former DOJ Fraud Section Prosecutors. Nationwide Defense for Infusion Center Owners, Oncologists, Specialty Pharmacies, Physicians, and Healthcare Executives Facing Federal Injection and Infusion Therapy Fraud Investigations and Charges.
Based in Washington, D.C., Armstrong & Bradylyons PLLC defends infusion center owners, oncologists, specialty pharmacy operators, prescribing physicians, nurse practitioners, medical directors, marketers, and healthcare executives in federal injection and infusion therapy fraud investigations and cases nationwide.
The firm’s healthcare fraud defense practice is built on nearly a decade of combined experience at the nation’s preeminent healthcare fraud enforcement unit: the Healthcare Fraud Unit of DOJ’s Fraud Section. Scott Armstrong, Drew Bradylyons, and Andrea Savdie tried 17 federal jury trials in healthcare fraud cases at DOJ’s Fraud Section involving over $2.8 billion in alleged false and fraudulent claims to federal healthcare programs. The firm’s attorneys investigated and tried injection and infusion fraud cases in federal court at DOJ and know how the government constructs these cases for trial.
Injection and infusion therapy fraud is a high-value enforcement target for the Medicare Fraud Strike Force because of the high reimbursement rates associated with injectable drugs, chemotherapy agents, and biologic therapies. The firm defends individuals in every federal district where DOJ and HHS-OIG bring injection and infusion fraud cases.
Armstrong & Bradylyons PLLC defends every injection and infusion therapy fraud case from the start as if it will go to trial. That is not a slogan. It is the operating principle of the firm, grounded in 25 federal jury trials in complex fraud cases in federal courts across the country.
Trial experience drives results at every stage. Injection and infusion therapy fraud cases are built on J-code and CPT billing analysis, pharmaceutical distribution records, drug inventory comparisons, and cooperating witness testimony. They involve allegations of billing for drugs never purchased or administered, upcoding drug administration codes, billing for higher-cost medications when cheaper alternatives were used, waste-and-discard fraud, and kickback arrangements for patient referrals. The firm builds the factual record from the first day of engagement: analyzing claims data, retaining pharmacology and oncology experts, identifying and preparing witnesses, and developing a case theory that can withstand the government’s scrutiny.
The firm’s attorneys know how federal prosecutors build healthcare fraud cases because they built them. Scott Armstrong served for nearly a decade at DOJ’s Fraud Section, where he served as lead trial counsel in 16 federal jury trials, including complex healthcare fraud cases involving Medicare, Medicaid, and Tricare. Drew Bradylyons served as Chief of EDVA’s Financial Crimes and Public Corruption Unit and, before that, supervised the Healthcare Fraud Unit’s Miami Strike Force at DOJ’s Fraud Section. That combined experience provides the firm with an unmatched understanding of how federal healthcare fraud cases are investigated, charged, and tried.
The firm relishes the opportunity to try cases. Its willingness to go to trial and its proven skills at trial provide significant leverage in negotiations with federal prosecutors at every stage of an injection and infusion therapy fraud case.
Injection and infusion therapy fraud is a persistent enforcement target for DOJ’s Health Care Fraud Unit. The economics make it inevitable. Injectable drugs, chemotherapy agents, and biologic therapies command some of the highest reimbursement rates in the Medicare program. A single infusion can generate thousands of dollars in reimbursement. That reimbursement structure creates powerful financial incentives for upcoding, waste-and-discard fraud, and kickback-driven referral arrangements.
DOJ’s 2025 Year in Review highlighted prosecutions where fraudulent conduct resulted in unnecessary infusions. The Health Care Fraud Unit’s Data Analytics Team identified a California facility that billed Medicare for Botox injections to treat chronic migraines, including injections allegedly administered at times when the facility was closed. That data-driven investigation led to an October 2025 indictment of the facility’s owner. This case illustrates how the government uses claims data analytics to detect injection fraud in real time.
The enforcement pattern is well established. An Orlando physician and infusion clinic owner were sentenced to 64 months and 90 months in federal prison for a $13.7 million infusion therapy fraud scheme. They submitted claims for expensive infusion-therapy drugs that were never purchased, never provided, and not medically necessary. In 2025, a Gilead Sciences settlement of $202 million resolved allegations that the company used speaker programs to pay kickbacks to physicians who prescribed its drugs, many of which are administered by injection or infusion.
CMS suspended $5.7 billion in suspected fraudulent Medicare payments in 2025 by leveraging advanced analytics and cross-agency coordination. The government’s Health Care Fraud Data Fusion Center combines data from DOJ, HHS-OIG, FBI, and CMS to detect anomalous billing in real time. Infusion centers and specialty practices with billing patterns that diverge from peer averages are being identified faster than ever before.
The HHS-OIG Work Plan continues to target drug administration billing, waste-and-discard practices, and the use of buy-and-bill models where providers purchase drugs at discounted rates and bill Medicare at higher reimbursement levels. Providers who profit from the spread between acquisition cost and reimbursement face particular scrutiny when that spread appears to drive clinical decisions.
The firm’s injection and infusion therapy fraud defense practice is built on healthcare fraud trial experience, deep knowledge of Medicare Part B drug reimbursement rules, and years of experience investigating and prosecuting complex healthcare fraud cases at DOJ’s Fraud Section. These tools are deployed at every phase of a case.
Challenging the Government’s J-Code and CPT Billing Analysis
The government builds injection and infusion fraud cases on billing code analysis. Federal investigators compare J-codes for injectable drugs, CPT codes for drug administration services, and modifier usage against peer benchmarks and CMS billing guidelines. They identify upcoding, unbundling, and billing patterns that diverge from statistical norms. The firm retains billing and coding experts to challenge the government’s methodology, contest outlier designations, and demonstrate that coding practices were consistent with applicable Medicare guidelines and the services actually provided.
Establishing Medical Necessity for Injectable Treatments
The government’s case often hinges on the claim that injections or infusions were medically unnecessary. The firm retains independent pharmacology, oncology, pain management, and rheumatology experts to evaluate whether the treatment at issue met applicable clinical standards, was consistent with the patient’s documented condition, and was supported by the clinical record. The government’s medical necessity opinion is an opinion. It must be tested at trial through cross-examination. The firm builds the clinical record to withstand that scrutiny.
Challenging Waste-and-Discard and Drug Diversion Allegations
Federal prosecutors compare the volume of drugs billed to Medicare against the volume of drugs purchased from wholesalers and distributors. If the numbers do not reconcile, the government alleges that claims were submitted for drugs that were never purchased or administered. The firm retains pharmaceutical distribution experts and forensic accountants to analyze purchase records, inventory logs, and waste-and-discard documentation. Discrepancies between billing and purchasing records do not automatically prove fraud. The firm identifies legitimate explanations and presents them forcefully.
Challenging the Government’s Proof of Knowledge and Intent
Federal healthcare fraud requires proof of willful and knowing fraud. Clinical decisions about treatment protocols, drug selection, and dosing involve professional medical judgment. The firm builds the factual record to demonstrate that the provider acted in good faith, that clinical staff exercised legitimate professional judgment, and that the provider did not intend to defraud Medicare. Where the government relies on cooperating witness testimony to establish intent, the firm attacks the reliability, credibility, and motivations of those witnesses. The firm’s attorneys have extensive experience cross-examining cooperating witnesses in federal healthcare fraud trials.
Federal injection and infusion therapy fraud investigations target individuals at every level of the operation: from the physicians who prescribe and administer treatments, to the infusion center owners who control the business, the specialty pharmacies that dispense drugs, and the marketers who recruit patients. Armstrong & Bradylyons PLLC defends these individuals in federal investigations, after indictment, and at trial.
Defense of Infusion Center Owners and Operators
The firm defends the founders, owners, and operators of infusion centers, IV therapy clinics, and outpatient infusion suites in federal fraud, Anti-Kickback Statute, and money laundering investigations and prosecutions. Infusion center owners are primary enforcement targets. Prosecutors pursue owners who allegedly directed billing for drugs never purchased or administered, designed compensation structures that incentivized medically unnecessary infusions, paid kickbacks for patient referrals, or submitted claims using provider identifiers without authorization. The firm defends infusion center owners by challenging the government’s evidence of personal knowledge, direction, and intent.
Defense of Oncologists and Prescribing Physicians
The firm defends oncologists, pain management physicians, rheumatologists, neurologists, and other prescribing physicians in federal injection and infusion fraud cases. Physicians face criminal exposure when the government alleges they prescribed medically unnecessary infusions, selected higher-cost drugs when cheaper therapeutic alternatives were available, received kickbacks from drug manufacturers or infusion centers for prescribing decisions, or participated in schemes to bill for treatments not provided. The firm defends physicians by establishing the clinical basis for treatment decisions and challenging the government’s characterization of legitimate medical judgment.
Defense of Specialty Pharmacy Operators
The firm defends specialty pharmacy owners, pharmacists, and operators in federal infusion fraud investigations. Specialty pharmacies face exposure when the government alleges they dispensed medications not prescribed or not delivered, participated in buy-and-bill schemes with inflated reimbursement, paid kickbacks for prescription referrals, or billed for compounded drugs at rates that exceeded the cost of commercially available alternatives. The firm defends specialty pharmacy operators by challenging the government’s evidence and analyzing compensation arrangements against AKS safe harbor regulations.
Defense of Medical Directors and Nurse Practitioners
The firm defends medical directors, nurse practitioners, and clinical staff who face federal charges in injection and infusion fraud cases. Medical directors face exposure when the government alleges they authorized medically unnecessary treatments, served as sham medical directors for infusion centers, allowed their provider identifiers to be used for billing without their knowledge, or received compensation tied to the volume of infusions ordered. The firm defends medical professionals by establishing the legitimacy of their clinical roles and challenging the government’s evidence of fraudulent intent.
Defense of Marketers and Sales Representatives
The firm defends pharmaceutical sales representatives, marketers, and referral agents who face federal charges in injection and infusion fraud cases. Marketers face exposure when the government alleges they paid kickbacks to physicians for prescribing specific injectable drugs, facilitated speaker program payments that were actually kickbacks disguised as honoraria, or recruited patients for infusion centers through improper financial inducements. The firm defends marketers by analyzing compensation structures and challenging the government’s theory that legitimate promotional activity constituted illegal kickback arrangements.
Federal injection and infusion therapy fraud investigations follow a pattern. Understanding that pattern is the first step to defending against it. Scott Armstrong and Drew Bradylyons built these types of cases as senior prosecutors at DOJ’s Fraud Section. They know how federal investigators identify targets, develop evidence, and present cases to grand juries.
J-Code and CPT Billing Analysis
The investigation starts with billing data. HHS-OIG, CMS, and the FBI analyze J-code and CPT claims data to identify providers with anomalous billing patterns. The government flags providers who bill disproportionately high volumes of high-reimbursement injectable drugs, who consistently use higher-paying drug administration codes, who bill for more units of a drug than are clinically typical for the documented diagnosis, or whose waste-and-discard billing suggests systematic overbilling. The Health Care Fraud Data Fusion Center deploys advanced analytics to detect these patterns in real time.
Drug Purchase and Inventory Reconciliation
Federal investigators subpoena pharmaceutical distribution records from drug wholesalers and compare the volume of drugs purchased against the volume billed to Medicare. If a provider billed for 1,000 vials of a drug but purchased only 500, the government has a straightforward case for phantom billing. Investigators also analyze National Drug Code (NDC) data, lot numbers, and expiration dates to trace individual drug units through the supply chain. Drug inventory reconciliation is one of the most powerful tools in the government’s arsenal for injection fraud prosecutions.
Waste-and-Discard Analysis
Medicare reimburses providers for the full vial of a single-use drug even if the patient receives less than the full vial. The remainder is classified as waste. The government investigates whether providers systematically billed for waste that did not occur, used the discarded portions of single-use vials on additional patients, or selected vial sizes that maximized waste reimbursement. Waste-and-discard fraud is a significant component of many injection fraud prosecutions because the financial incentives are substantial and the billing patterns are detectable through claims data analysis.
Kickback and Referral Analysis
The government investigates financial relationships between infusion centers, prescribing physicians, drug manufacturers, specialty pharmacies, and marketers. Prosecutors examine whether infusion centers paid kickbacks to physicians for patient referrals, whether drug manufacturers used speaker programs, consulting agreements, or research grants to induce physicians to prescribe specific injectable drugs, and whether specialty pharmacies paid kickbacks for prescription referrals. Investigators trace payments through bank records, contracts, and compensation arrangements to identify relationships that correlate with referral volume.
Patient and Employee Interviews
Federal agents from the FBI and HHS-OIG interview current and former employees, patients, nurses, and billing staff. They look for cooperating witnesses who can testify about whether drugs were actually administered, whether treatments were medically necessary, whether documentation was fabricated, whether physician orders were legitimate, and whether kickback payments were made. Cooperating witnesses provide the narrative that connects data anomalies to individual intent.
Search Warrants and Electronic Evidence
Federal agents routinely seek and execute search warrants for cell phones, laptops, and cloud-based accounts in injection and infusion fraud investigations. These warrants target communications between infusion center owners, physicians, pharmacy operators, and billing staff that reveal knowledge of fraudulent billing practices, directives to upcode drug administration services, discussions about kickback payments, and efforts to conceal the true nature of billing practices. Federal agents obtain cloud warrants under 18 U.S.C. § 2703 of the Stored Communications Act.
Federal injection and infusion therapy fraud prosecutions draw on several criminal statutes. The government charges aggressively and stacks counts. Understanding the statutory framework is essential to mounting an effective defense.
Healthcare Fraud (18 U.S.C. § 1347)
The primary charging statute in injection and infusion fraud cases. Healthcare fraud makes it a federal crime to knowingly and willfully execute or attempt to execute a scheme to defraud any healthcare benefit program. In injection and infusion cases, this statute targets billing for drugs never purchased or administered, upcoding drug administration codes, billing for medically unnecessary treatments, and waste-and-discard fraud. The penalty is up to 10 years of imprisonment per count. If the fraud results in serious bodily injury, the maximum increases to 20 years. If it results in death, a life sentence is possible.
Wire Fraud (18 U.S.C. § 1343)
The government frequently charges wire fraud alongside or as an alternative to healthcare fraud. Wire fraud applies to any scheme to defraud that uses interstate wire communications, which includes the electronic submission of Medicare claims. Wire fraud carries a maximum penalty of 20 years of imprisonment per count.
Anti-Kickback Statute (42 U.S.C. § 1320a-7b)
The Anti-Kickback Statute is frequently charged in injection and infusion fraud cases. It prohibits offering, paying, soliciting, or receiving anything of value to induce or reward referrals for services covered by federal healthcare programs. In injection cases, prosecutors target kickbacks from drug manufacturers to prescribing physicians, kickbacks from infusion centers to referring physicians, and kickbacks disguised as speaker program fees, consulting agreements, or research grants. Violations carry up to 10 years of imprisonment per violation.
Money Laundering (18 U.S.C. §§ 1956, 1957)
Money laundering charges are common in large-scale injection and infusion fraud prosecutions. The government charges money laundering when it alleges that defendants conducted financial transactions involving fraud proceeds with the intent to conceal or promote the underlying scheme. Money laundering carries up to 20 years of imprisonment per count.
False Claims Act (31 U.S.C. §§ 3729–3733)
The False Claims Act is the government’s primary civil enforcement tool in injection and infusion fraud cases. FCA penalties include treble damages and per-claim penalties. Many investigations run parallel criminal and civil tracks. Drug manufacturer settlements under the FCA for kickback-related conduct have reached hundreds of millions of dollars. FCA cases may be brought by the government directly or by private whistleblowers through the Act’s qui tam provisions.
Federal Program Exclusion and Collateral Consequences
Beyond incarceration and fines, a conviction or settlement in an injection and infusion fraud case triggers mandatory exclusion from Medicare, Medicaid, and all federal healthcare programs under the authority of HHS-OIG. For physicians and licensed professionals, exclusion effectively ends a medical career. State medical licensing boards may initiate independent disciplinary proceedings. DEA registration may be revoked if the case involves controlled substance infusions.
What Types of Injection and Infusion Therapy Fraud Does the Government Prosecute?
Federal prosecutors target several categories of injection and infusion therapy fraud. The most common are billing for injectable drugs that were never purchased or administered, upcoding drug administration CPT codes to generate higher reimbursement, billing for higher-cost medications when cheaper therapeutic alternatives were used, waste-and-discard fraud involving single-use vials, kickback arrangements between infusion centers and referring physicians, and kickbacks from drug manufacturers to prescribing physicians disguised as speaker fees, consulting agreements, or research grants.
DOJ’s 2025 Year in Review highlighted unnecessary infusions as a prosecution priority. The Health Care Fraud Unit’s Data Analytics Team identified a California facility billing Medicare for Botox injections at times when the facility was closed, leading to an October 2025 indictment.
What Is Waste-and-Discard Fraud in Injection Cases?
Medicare reimburses providers for the full vial of a single-use injectable drug even if the patient receives less than the full amount. The unused portion is classified as waste. Waste-and-discard fraud occurs when providers bill for waste that did not occur, use discarded portions of single-use vials on additional patients (and then bill Medicare for a full vial for each patient), or select vial sizes that maximize the amount of billable waste.
The government detects waste-and-discard fraud by comparing the number of drug units billed against the number of units purchased. If a provider consistently bills for more units than it purchased, the discrepancy is strong evidence of fraud. An experienced healthcare fraud defense attorney challenges the government’s calculations by analyzing drug inventory records, waste documentation, and CMS billing guidelines.
What Are the Penalties for a Federal Injection or Infusion Therapy Fraud Conviction?
The penalties are severe. Healthcare fraud carries up to 10 years per count. Wire fraud carries up to 20 years per count. Money laundering carries up to 20 years per count. Anti-Kickback Statute violations carry up to 10 years per violation.
An Orlando physician and infusion clinic owner were sentenced to 64 months and 90 months in federal prison for a $13.7 million infusion therapy fraud scheme. Federal sentencing in injection fraud cases is driven by the loss amount. High-reimbursement injectable drugs generate large loss figures quickly. Beyond prison, defendants face restitution, forfeiture, and mandatory exclusion from federal healthcare programs.
How Does the Government Use Drug Purchase Records to Build an Injection Fraud Case?
Federal investigators subpoena pharmaceutical distribution records from drug wholesalers and compare the volume of drugs a provider purchased against the volume billed to Medicare. If a provider billed for 1,000 vials but purchased only 500, the government has a straightforward case for phantom billing.
Investigators also analyze National Drug Code (NDC) data, lot numbers, and expiration dates to trace individual drug units through the supply chain. The reconciliation of purchase records against billing records is one of the most powerful tools in the government’s arsenal. An experienced defense attorney challenges the completeness and accuracy of the government’s inventory analysis.
What Defenses Are Available in a Federal Injection or Infusion Therapy Fraud Case?
The available defenses depend on the specific allegations. Common defenses include the following:
Medical necessity. Retaining independent oncology, pharmacology, or pain management experts to demonstrate that injectable treatments were clinically appropriate.
Billing accuracy. Retaining coding and billing experts to demonstrate that J-code and CPT code usage was consistent with CMS guidelines.
Drug inventory reconciliation. Challenging the government’s purchase-versus-billing analysis with complete inventory records and waste documentation.
Good faith reliance. Presenting evidence of compliance programs, reliance on legal counsel, or CMS guidance.
Cross-examining cooperators. Attacking the credibility of cooperating witnesses who have plea agreements and sentencing incentives to implicate others.
Scott Armstrong and Drew Bradylyons leverage their significant federal trial experience as former prosecutors to anticipate the government’s trial strategy and develop an aggressive, evidence-based defense.
What Triggers a Federal Injection or Infusion Therapy Fraud Investigation?
Federal injection and infusion fraud investigations are typically triggered by CMS claims data analytics identifying billing outliers, HHS-OIG audits of drug administration billing, drug wholesaler reports of unusual purchasing patterns, qui tam whistleblower complaints filed by former employees under the False Claims Act, complaints from patients or insurance carriers, and referrals from drug manufacturers who detect anomalous prescribing patterns.
Common red flags include unusually high volumes of high-reimbursement injectable drugs, disproportionate billing for costly drug administration codes, purchase-versus-billing discrepancies, and rapid growth in infusion volume relative to patient population.
Can a Physician Be Charged for Prescribing a Higher-Cost Injectable Drug?
Prescribing a higher-cost drug is not automatically fraud. Physicians exercise clinical judgment in selecting treatments. The government must prove that the physician knowingly and willfully prescribed the higher-cost drug not for clinical reasons but to generate higher reimbursement or in exchange for kickback payments.
The government builds these cases by showing a pattern of prescribing the most expensive option when cheaper, clinically equivalent alternatives existed, combined with evidence of financial incentives. Speaker program payments, consulting fees, or other compensation from the drug manufacturer can be characterized as kickbacks that influenced prescribing decisions. An experienced defense attorney establishes the clinical basis for drug selection and challenges the government’s characterization of legitimate medical judgment.
How Do Kickbacks from Drug Manufacturers Create Federal Exposure for Physicians?
Drug manufacturer kickback schemes are a major enforcement target. The government alleges that manufacturers use speaker programs, consulting agreements, advisory board fees, and research grants to induce physicians to prescribe their injectable products. If the government proves that the payment was intended to induce prescribing rather than compensate for a legitimate service, both the manufacturer and the physician face Anti-Kickback Statute liability.
In 2025, Gilead Sciences settled for $202 million to resolve allegations that it used speaker programs to pay kickbacks to physicians to induce them to prescribe its drugs. Physicians who receive manufacturer payments and prescribe that manufacturer’s injectable products face significant federal exposure.
What Is the Buy-and-Bill Model and Why Does It Attract Enforcement Scrutiny?
Under the buy-and-bill model, providers purchase injectable drugs directly from wholesalers and then bill Medicare Part B for reimbursement based on the drug’s Average Sales Price (ASP) plus a statutory add-on (currently ASP + 6%). Providers profit from the spread between their acquisition cost and the Medicare reimbursement rate.
The model is legal. But it creates enforcement risk when the government alleges that the spread between acquisition cost and reimbursement drives clinical decisions. If a provider selects a more expensive drug because the reimbursement spread is wider, the government may allege that the prescribing decision was driven by financial incentives rather than clinical judgment. The government also scrutinizes whether providers received additional discounts, rebates, or kickbacks from manufacturers that reduced their acquisition cost below the reported ASP.
Does Armstrong & Bradylyons Handle Injection and Infusion Fraud Cases Nationwide?
Yes. Armstrong & Bradylyons PLLC defends individuals in federal injection and infusion therapy fraud investigations and prosecutions nationwide. The firm can practice in every federal district court in the country.
Injection and infusion fraud enforcement is concentrated in Strike Force districts including the Southern District of Florida, the Central District of California, the Southern District of Texas, the Eastern District of New York, the Northern District of Illinois, and the Middle District of Florida.
Scott Armstrong and Drew Bradylyons have tried healthcare fraud cases and handled investigations in federal courts throughout the country during their combined 25-year DOJ career. The firm is based in Washington, D.C. and represents clients in every jurisdiction where DOJ, CMS, and HHS-OIG investigate and prosecute injection and infusion therapy fraud cases.